Organization (Industry)
CellSight Technologies (United States)
ClinicalTrials.gov lists CellSight Technologies (United States) as lead sponsor of 11 trials. It has 10 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers CellSight Technologies (United States): 11 lead-sponsored trials and 1 legal-entity registration.
Disease areas (15)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 7 |
| Lung Neoplasms | 7 |
| Carcinoma, Squamous Cell | 2 |
| Head and Neck Neoplasms | 2 |
| Squamous Cell Carcinoma of Head and Neck | 2 |
Showing 5 of 15 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 5 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 4 |
| 2015 | 1 |
Prediction, not a registry value: median of 27 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (10)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| [ 18F]F-AraG PET | Lung Neoplasms | Phase 2 | 1 |
| Drug: [18F]F-AraG (PET tracer) | Dementia | Phase 2 | 1 |
| [ 18F]F-AraG PET | Carcinoma, Non-Small-Cell Lung | Phase 2 | 1 |
| [18F]F AraG | COVID-19 | Phase 2 | 1 |
| [18F]F AraG | HIV Infections | Phase 2 | 1 |
Showing 5 of 10 active programs.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 3 hit target (n=3) | 0 of 3 on time (n=3) |
Journals published in (4)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Cancer research | 2 |
| Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 1 |
| Molecular imaging | 1 |
| Molecular imaging and biology | 1 |
Financing and grant events (2)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-18 | SBIR award | 871,261 | Reporter |
| 2022-09-30 | SBIR award | 1,995,174 | Reporter |
Organization relationships (6)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of California System | Co sponsors trial with | 6 |
| Government of the United States of America | Co sponsors trial with | 3 |
| Stand Up To Cancer | Co sponsors trial with | 1 |
| Diwakar Davar | Co sponsors trial with | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Co sponsors trial with | 1 |
Showing 5 of 6 relationships.
Latest dated events (22)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-18 | SBIR award | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2023-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-10-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 22 events.
Biomarker capability evidence (26)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD274 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| F2 | Trial collaborator | Named in trial inclusion criteria |
| F3 | Trial collaborator | Named in trial inclusion criteria |
| PDCD1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 26 evidence rows.
On Scientist.com
CellSight Technologies (United States) is listed as a research supplier in the Scientist.com network.
CellSight is enabling therapies in living subjects through the use of imaging technologies. We are developing PET imaging tracers to be used as companion diagnostics for immunotherapy to help determine efficacy early to enable regimen modification.
We also offer custom imaging research services to enable therapy developers to incorporate imaging during therapy development cycle. We have formed partnerships with several pharmaceutical companies and academia.
- Website
- cellsighttech.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with CellSight Technologies on Scientist.com
For prices, more details, or to contact CellSight Technologies, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.